Skip to content

Released Nov 6, 2025, after the close

10-Q filed Nov 6, 2025, 37 days after period end · 0001628280-25-050193

Q3 2025 · 10-Q
Revenue$29.38M−67.0% vs Q3 2024−24.9% vs Q2 2025
Net Income-$80.76MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$1.45N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$82,305,000N/M
Operating Cash Flowderived-$31,606,000N/M
Free Cash Flowderived-$31,606,000N/M
Margins · derived
Operating margin-280.1%−218.1 pt vs Q3 2024
Net margin-274.9%−211.5 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$29.38M$89.05M$55.43M$66.40M
Net Income-$80.76M-$56.40M-$302.89M-$670.13M
EPS Diluted-$1.45-$1.08-$6.21-$0.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR